Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06VZS
|
||||
| Former ID |
DIB020612
|
||||
| Drug Name |
ONO-AE1-329
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539233] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H32O6S2
|
||||
| InChI |
InChI=1S/C23H32O6S2/c1-29-14-17-6-3-2-5-16(17)7-8-18(24)9-10-19-20(25)13-21(26)23(19)31-12-4-11-30-15-22(27)28/h2-3,5-6,9-10,18-20,23-25H,4,7-8,11-15H2,1H3,(H,27,28)/b10-9+/t18-,19-,20+,23+/m0/s1
|
||||
| InChIKey |
BVGVPUMSPSNRRQ-CNOJNPITSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin E2receptor, EP2 subtype | Target Info | Agonist | [525735] | |
| Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [525735] | ||
| Prostaglandin E2 receptor, EP4 subtype | Target Info | Agonist | [525735] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
| Pathways in cancer | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.